Industry

New study shows Probi strain supports and improves cognitive performance

In a newly published study Probi´s proprietary strain L. plantarum HEAL9 (HEAL9™) was shown to significantly improve cognitive performance.

New study asserts resB® Lung Support improves lung function in asthmatic population

A new study asserts resB® Lung Support improves lung function through microbiome-mediated mechanisms along the gut-lung axis in asthmatic population

New clinical study shows clear benefits of Probi’s probiotics for Metabolic Health

A new study demonstrated that daily intake of Probi's proprietary strain Lacticaseibacillus paracasei 8700:2 significantly reduced cardiovascular disease risk.

Microbiome Movement Drug Development – Congress Report

With all aspects of LBPs covered in the summit, the 8th Microbiome Movement Summit in Boston became the hub for sharing the latest insights in LBP research and development.

MaaT Pharma announces publication of results in eClinicalMedicine Journal highlighting clinical benefit of MaaT013 in aGvHD

Ongoing Phase 3 trial built on positive data from Phase 2 HERACLES study and ongoing early access program (EAP) in France: both datasets showed that MaaT013 was well-tolerated in immunocompromised…

MICRO beyond the analysis: linking people, research and innovation

The microbiological laboratory applying AI to specific analysis activities.

Alphyn Biologics Reports Encouraging Interim Results of Phase 2a Trial for Atopic Dermatitis with Secondary Bacterial Infection

Topical treatment is achieving all endpoints for efficacy and safety in mild, moderate, and severe atopic dermatitis.

Nestlé partners with APC Microbiome Ireland

The collaboration will focus on various aspects of the human microbiome that could benefit new product development.

Additional Infant Bacterial Therapeutics product receives FDA orphan drug designation

The FDA has granted orphan drug designation for IBT’s product IBP-1016 for gastroschisis.

Adare Pharma Solutions announces divestiture of postbiotics pioneer Adare Biome to dsm-firmenich

The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x.

Subscribe to MicrobiomePost newsletter

Take full advantage of MicrobiomePost‘s features.